Clarivate posts Q3 loss, beats EPS but misses revenue after Life Sciences divestiture
Clarivate Plc reported third‑quarter 2026 results on Nov. 3, 2026. Revenue for continuing operations was $481.6 million, down 9.2% year‑over‑year, while adjusted earnings per share were $0.21, beating estimates. The company recorded a net loss of $80.8 million, including a $62.2 million non‑cash goodwill impairment from the recently completed Life Sciences & Healthcare divestiture. Management updated full‑year guidance, forecasting FY‑2026 revenue of $1.96‑$1.98 billion, below analyst consensus.
Why it matters
The revenue miss and lower FY‑2026 guidance suggest weaker top‑line growth than expected, which may pressure the stock price. The EPS beat and improved margins provide some offset, but investors must weigh the impact of the divestiture‑related impairment and the revised outlook.
Key facts
- 1Total revenues were $567.9 million, including the Life Sciences & Healthcare segment, which was divested on October 6, 2026. prnewswire.com
- 2Excluding the divested segment, continuing‑operations revenue was $481.6 million, down from $530.3 million a year earlier. prnewswire.com
- 3Adjusted net income, including the divested segment, was $136.0 million, or $0.21 per diluted share, versus $119.3 million, or $0.18 per share, in Q3 2025. prnewswire.com
- 4Net loss, including the divested segment, was $80.8 million, or $0.13 per diluted share, driven by a $62.2 million non‑cash goodwill impairment charge. prnewswire.com
- 5Organic revenues for continuing operations increased 0.4% year‑over‑year. prnewswire.com
- 6Full‑year 2026 revenue guidance was revised to $1.96‑$1.98 billion, below consensus of $2.20 billion. investing.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.